AntonVPower
Member
Fucken exactly bro! These POS's think we are dumb. At least, all of us are dumb. But hey, the Great Reset must happen so whatever it takes, right? Pieces of shit
MESO-Rx
Anabolic Steroids
Can touching a barbell in the gym get you sick with the coronavirus?
- Thread starter Michael Scally MD
- Start date
Villain
Member
Saddest part is, the sheep who buy into and spread this shit outnumber the ones who actually question the bullshit narrative.
Villain
Member
Speaking of the Great Reset..
And who is that "sleepy" guy in the front row at 30:07
Buy it on Amazon..
Description
"COVID-19: The Great Reset" is a guide for anyone who wants to understand how COVID-19 disrupted our social and economic systems, and what changes will be needed to create a more inclusive, resilient and sustainable world going forward. Klaus Schwab, founder and executive Chairman of the World Economic Forum, and Thierry Malleret, founder of the Monthly Barometer, explore what the root causes of these crisis were, and why they lead to a need for a Great Reset.Theirs is a worrying, yet hopeful analysis. COVID-19 has created a great disruptive reset of our global social, economic, and political systems. But the power of human beings lies in being foresighted and having the ingenuity, at least to a certain extent, to take their destiny into their hands and to plan for a better future. This is the purpose of this book: to shake up and to show the deficiencies which were manifest in our global system, even before COVID broke out."Erudite, thought-provoking and plausible" -- Hans van Leeuwen, Australian Financial Review (Australia)"The book looks ahead to what the post-coronavirus world could look like barely four months after the outbreak was first declared a pandemic" -- Sam Meredith, CNBC (USA) "The message that the pandemic is not only a crisis of enormous proportions, but that it also provides an opportunity for humanity to reflect on how it can do things differently, is important and merits reflection"-- Ricardo Avila, Portafolio (Colombia) "A call for political change in the post-pandemic world"-- Ivonne Martinez, La Razon (Mexico)"History has shown, the book argues, that pandemics are a force for radical and lasting change"-- Mustafa Alrawi, The National (UAE)
AntonVPower
Member
Yep, and nearly everyone i personally know who knows its BS still puts on their face diaper everywhere they go and reinforces the psyop even on themselves by complying. Fuck its frustrating to see the level of sheer gullibility and utter cowardice to resist
Villain
Member
I’m not sure where you stand with God/Bible/etc bro, and not trying to preach here but if you look about the Mark of the beast, i.e. one world government, they’re given a mark and those without it can neither buy, sell or trade. These mask mandates are basically doing the same thing. Psyop 100% to see who is complicit and who isn’t and how ripe we are for a takeover.
AntonVPower
Member
Speaking of the Great Reset..
And who is that "sleepy" guy in the front row at 30:07
Buy it on Amazon..
Description
"COVID-19: The Great Reset" is a guide for anyone who wants to understand how COVID-19 disrupted our social and economic systems, and what changes will be needed to create a more inclusive, resilient and sustainable world going forward. Klaus Schwab, founder and executive Chairman of the World Economic Forum, and Thierry Malleret, founder of the Monthly Barometer, explore what the root causes of these crisis were, and why they lead to a need for a Great Reset.Theirs is a worrying, yet hopeful analysis. COVID-19 has created a great disruptive reset of our global social, economic, and political systems. But the power of human beings lies in being foresighted and having the ingenuity, at least to a certain extent, to take their destiny into their hands and to plan for a better future. This is the purpose of this book: to shake up and to show the deficiencies which were manifest in our global system, even before COVID broke out."Erudite, thought-provoking and plausible" -- Hans van Leeuwen, Australian Financial Review (Australia)"The book looks ahead to what the post-coronavirus world could look like barely four months after the outbreak was first declared a pandemic" -- Sam Meredith, CNBC (USA) "The message that the pandemic is not only a crisis of enormous proportions, but that it also provides an opportunity for humanity to reflect on how it can do things differently, is important and merits reflection"-- Ricardo Avila, Portafolio (Colombia) "A call for political change in the post-pandemic world"-- Ivonne Martinez, La Razon (Mexico)"History has shown, the book argues, that pandemics are a force for radical and lasting change"-- Mustafa Alrawi, The National (UAE)
James Corbett is a hero. Needs to workout and prepare for the times ahead by say, eating some food..., but one of the absolute best researchers of our time.
Ol' Satan Klaus. Have you read his Fourth Industrial Revolution? Basically a conceptual outline of the biosecurity nightmare that we are walking into now with heavy Huxley and Orwellian overtones couched in, none other, "progress". Fuck these times bro
[OA] Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality
Highlights
The COVID-19 pandemic showed a different morbidity and mortality in males versus females and in elderly versus young people.
Sex hormones as well as associated comorbidities can play a role in the pathogenesis and the management of COVID-19 infection.
Both oestrogen and androgen influence the function of important target organs for COVID-19.
Answering the underlying questions could help develop more effective and sex-specific prevention and treatment strategies.
The recent coronavirus disease 2019 (COVID-19) pandemic showed a different severity in the disease between males and females. Men have been becoming severely ill at a higher rate than women.
These data along with an age-dependent disease susceptibility and mortality in the elderly suggest that sex hormones are the main factors in determining the clinical course of the infection.
The differences in aging males versus females and the role of sex hormones in key phenotypes of COVID-19 infection are described in this review. Recommendations based on a dimorphic approach for males and females suggest a sex-specific management the disease.
Brandi ML, Giustina A. Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality. Trends Endocrinol Metab. 2020 Sep 24:S1043-2760(20)30181-8. doi: 10.1016/j.tem.2020.09.003. Epub ahead of print. PMID: 33082024. https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(20)30181-8
Highlights
The COVID-19 pandemic showed a different morbidity and mortality in males versus females and in elderly versus young people.
Sex hormones as well as associated comorbidities can play a role in the pathogenesis and the management of COVID-19 infection.
Both oestrogen and androgen influence the function of important target organs for COVID-19.
Answering the underlying questions could help develop more effective and sex-specific prevention and treatment strategies.
The recent coronavirus disease 2019 (COVID-19) pandemic showed a different severity in the disease between males and females. Men have been becoming severely ill at a higher rate than women.
These data along with an age-dependent disease susceptibility and mortality in the elderly suggest that sex hormones are the main factors in determining the clinical course of the infection.
The differences in aging males versus females and the role of sex hormones in key phenotypes of COVID-19 infection are described in this review. Recommendations based on a dimorphic approach for males and females suggest a sex-specific management the disease.
Brandi ML, Giustina A. Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality. Trends Endocrinol Metab. 2020 Sep 24:S1043-2760(20)30181-8. doi: 10.1016/j.tem.2020.09.003. Epub ahead of print. PMID: 33082024. https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(20)30181-8
Villain
Member
BREAKING NEWS: The world renowned experts in their fields, after a 4 day conference regarding COVID-19, declare that WE SHOULD ALL GO BACK TO LIVING NORMALLY, PRACTICING SIMPLE HYGIENE & STAYING HOME WHEN SICK (NO FACE MASKS OR SOCIAL DISTANCING) and only protect the most vulnerable populations with more protective measures!
“From October 1-4, 2020, the American Institute for Economic Research had a remarkable meeting of top epidemiologists, economists, and journalists, to discuss the global emergency created by the unprecedented use of state compulsion in the management of the Covid-19 pandemic. The result is The Great Barrington Declaration, which urges a “Focused Protection” strategy.”
“Schools and universities should be open for in-person teaching. Extracurricular activities, such as sports, should be resumed. Young low-risk adults should work normally, rather than from home. Restaurants and other businesses should open. Arts, music, sport and other cultural activities should resume.”
Signed by:
Dr. Martin Kulldorff, Professor, Medicine, Harvard Medical School.
Dr. Jay Bhattacharya, Professor, Medicine, Stanford University.
Dr. Sunetra Gupta, Professor, Theoretical Epidemiology, University of Oxford.
The co-signers include
Dr. Rodney Sturdivant, PhD. associate professor of biostatistics at Baylor University and the Director of the Baylor Statistical Consulting Center. He is a Colonel in the US Army (retired) whose research includes a focus on infectious disease spread and diagnosis.
Dr. Eitan Friedman, MD, PhD. Founder and Director, The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center and Professor of Medicine, Department of Internal Medicine and Depertment of Human Genetics and Biochemistry, Tel-Aviv University
Dr. Rajiv Bhatia, MD, MPH a physician with the VA health system with expertise in epidemiology, health equity practice, and health impact assessment of public policy. He formerly served as a Deputy Health Officer for San Francisco for 18 years.
Dr. Michael Levitt, PhD is a biophysicist and a professor of structural biology at Stanford University. Prof. Levitt received the 2013 Nobel Prize in Chemistry for the development of multiscale models for complex chemical systems.
Dr. Eyal Shahar, MD professor (emeritus) of public health at the University of Arizona, a physician, epidemiologist, with expertise in causal and statistical inference.
Dr. David Katz, MD, MPH, President, True Health Initiative and the Founder and Former Director of the Yale University Prevention Research Center
Dr. Laura Lazzeroni, PhD., professor of psychiatry and behavioral sciences and of biomedical data science at Stanford University Medical School, a biostatistician and data scientist
Dr. Simon Thornley, PhD is an epidemiologist at the University of Auckland, New Zealand. He has experience in biostatistics and epidemiological analysis, and has applied these to a range of areas including communicable and non-communicable diseases.
Dr. Michael Jackson, PhD is an ecologist and research fellow at the University of Canterbury, New Zealand.
Dr. Jonas Ludvigsson, pediatrician, epidemiologist and professor at Karolinska Institute and senior physician at Örebro University Hospital, Sweden.
Dr. Sylvia Fogel, autism expert and psychiatrist at Massachusetts General Hospital and instructor at Harvard Medical School, USA.
Dr. Andrius Kavaliunas, epidemiologist and assistant professor at Karolinska Institute, Sweden Prof. Udi Qimron, Chair, Department of Clinical Microbiology and Immunology, Tel Aviv University
Prof. Ariel Munitz, Department of Clinical Microbiology and Immunology, Tel Aviv University
Prof. Motti Gerlic, Department of Clinical Microbiology and Immunology, Tel Aviv University
Dr. Uri Gavish, an expert in algorithm analysis and a biomedical consultant
Prof. Ellen Townsend, Self-Harm Research Group, University of Nottingham, UK.
Dr. Paul McKeigue, professor of epidemiology in the University of Edinburgh and public health physician, with expertise in statistical modelling of disease.
Dr. Mario Recker, Associate Professor in Applied Mathematics at the Centre for Mathematics and the Environment, University of Exeter.
Prof. Mike Hulme, professor of human geography, University of Cambridge
Prof. Stephen Bremner, Professor of Medical Statistics, Brighton and Sussex Medical School, University of Sussex
Prof. Matthew Ratcliffe, Professor of Philosophy specializing in philosophy of mental health, University of York, UK
Prof. Lisa White, Professor of Modelling and Epidemiology Nuffield Department of Medicine, Oxford University, UK
Prof. Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, Department of Oncology, St. George’s, University of London
Dr. Cody Meissner, professor of pediatrics at Tufts University School of Medicine, an expert on vaccine development, efficacy and safety.
Dr. Helen Colhoun, professor of medical informatics and epidemiology in the University of Edinburgh and public health physician, with expertise in risk prediction.
Prof. Partha P. Majumder, PhD, FNA, FASc, FNASc, FTWAS National Science Chair, Distinguished Professor and Founder National Institute of Biomedical Genomics, KalyaniEmeritus Professor Indian Statistical Institute, Kolkata
Dr. Gabriela Gomes, professor at the University of Strathclyde, Glasgow, a mathematician focussing on population dynamics, evolutionary theory and infectious disease epidemiology.
Prof. Anthony J Brookes, Department of Genetics & Genome Biology, University of Leicester, UK
Prof. Simon Wood, professor at Edinburgh University, a statistician with expertise in statistical methodology, applied statistics and mathematical modelling in biology
Prof. David Livermore, Professor at University of East Anglia, a microbiologist with expertise in disease epidemiology, antibiotic resistance and rapid diagnostics
Prof. Sucharit Bhakdi, em. Professor of Medical Microbiology, University of Mainz, Germany
Prof. Yaz Gulnur Muradoglu,
Professor of Finance, Director at Behavioural Finance Working Group, School of Business and Management, Queen Mary University of London
Prof. Karol Sikora MA, PhD, MBBChir, FRCP, FRCR, FFPM, Medical Director of Rutherford Health, Oncologist, & Dean of Medicine
Ask yourself WHY this isn't flooding every news station and WHY they're still pushing fear and death?!
What’s it going to take to get your name on this list @Michael Scally MD?
“From October 1-4, 2020, the American Institute for Economic Research had a remarkable meeting of top epidemiologists, economists, and journalists, to discuss the global emergency created by the unprecedented use of state compulsion in the management of the Covid-19 pandemic. The result is The Great Barrington Declaration, which urges a “Focused Protection” strategy.”
“Schools and universities should be open for in-person teaching. Extracurricular activities, such as sports, should be resumed. Young low-risk adults should work normally, rather than from home. Restaurants and other businesses should open. Arts, music, sport and other cultural activities should resume.”
Signed by:
Dr. Martin Kulldorff, Professor, Medicine, Harvard Medical School.
Dr. Jay Bhattacharya, Professor, Medicine, Stanford University.
Dr. Sunetra Gupta, Professor, Theoretical Epidemiology, University of Oxford.
The co-signers include
Dr. Rodney Sturdivant, PhD. associate professor of biostatistics at Baylor University and the Director of the Baylor Statistical Consulting Center. He is a Colonel in the US Army (retired) whose research includes a focus on infectious disease spread and diagnosis.
Dr. Eitan Friedman, MD, PhD. Founder and Director, The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center and Professor of Medicine, Department of Internal Medicine and Depertment of Human Genetics and Biochemistry, Tel-Aviv University
Dr. Rajiv Bhatia, MD, MPH a physician with the VA health system with expertise in epidemiology, health equity practice, and health impact assessment of public policy. He formerly served as a Deputy Health Officer for San Francisco for 18 years.
Dr. Michael Levitt, PhD is a biophysicist and a professor of structural biology at Stanford University. Prof. Levitt received the 2013 Nobel Prize in Chemistry for the development of multiscale models for complex chemical systems.
Dr. Eyal Shahar, MD professor (emeritus) of public health at the University of Arizona, a physician, epidemiologist, with expertise in causal and statistical inference.
Dr. David Katz, MD, MPH, President, True Health Initiative and the Founder and Former Director of the Yale University Prevention Research Center
Dr. Laura Lazzeroni, PhD., professor of psychiatry and behavioral sciences and of biomedical data science at Stanford University Medical School, a biostatistician and data scientist
Dr. Simon Thornley, PhD is an epidemiologist at the University of Auckland, New Zealand. He has experience in biostatistics and epidemiological analysis, and has applied these to a range of areas including communicable and non-communicable diseases.
Dr. Michael Jackson, PhD is an ecologist and research fellow at the University of Canterbury, New Zealand.
Dr. Jonas Ludvigsson, pediatrician, epidemiologist and professor at Karolinska Institute and senior physician at Örebro University Hospital, Sweden.
Dr. Sylvia Fogel, autism expert and psychiatrist at Massachusetts General Hospital and instructor at Harvard Medical School, USA.
Dr. Andrius Kavaliunas, epidemiologist and assistant professor at Karolinska Institute, Sweden Prof. Udi Qimron, Chair, Department of Clinical Microbiology and Immunology, Tel Aviv University
Prof. Ariel Munitz, Department of Clinical Microbiology and Immunology, Tel Aviv University
Prof. Motti Gerlic, Department of Clinical Microbiology and Immunology, Tel Aviv University
Dr. Uri Gavish, an expert in algorithm analysis and a biomedical consultant
Prof. Ellen Townsend, Self-Harm Research Group, University of Nottingham, UK.
Dr. Paul McKeigue, professor of epidemiology in the University of Edinburgh and public health physician, with expertise in statistical modelling of disease.
Dr. Mario Recker, Associate Professor in Applied Mathematics at the Centre for Mathematics and the Environment, University of Exeter.
Prof. Mike Hulme, professor of human geography, University of Cambridge
Prof. Stephen Bremner, Professor of Medical Statistics, Brighton and Sussex Medical School, University of Sussex
Prof. Matthew Ratcliffe, Professor of Philosophy specializing in philosophy of mental health, University of York, UK
Prof. Lisa White, Professor of Modelling and Epidemiology Nuffield Department of Medicine, Oxford University, UK
Prof. Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, Department of Oncology, St. George’s, University of London
Dr. Cody Meissner, professor of pediatrics at Tufts University School of Medicine, an expert on vaccine development, efficacy and safety.
Dr. Helen Colhoun, professor of medical informatics and epidemiology in the University of Edinburgh and public health physician, with expertise in risk prediction.
Prof. Partha P. Majumder, PhD, FNA, FASc, FNASc, FTWAS National Science Chair, Distinguished Professor and Founder National Institute of Biomedical Genomics, KalyaniEmeritus Professor Indian Statistical Institute, Kolkata
Dr. Gabriela Gomes, professor at the University of Strathclyde, Glasgow, a mathematician focussing on population dynamics, evolutionary theory and infectious disease epidemiology.
Prof. Anthony J Brookes, Department of Genetics & Genome Biology, University of Leicester, UK
Prof. Simon Wood, professor at Edinburgh University, a statistician with expertise in statistical methodology, applied statistics and mathematical modelling in biology
Prof. David Livermore, Professor at University of East Anglia, a microbiologist with expertise in disease epidemiology, antibiotic resistance and rapid diagnostics
Prof. Sucharit Bhakdi, em. Professor of Medical Microbiology, University of Mainz, Germany
Prof. Yaz Gulnur Muradoglu,
Professor of Finance, Director at Behavioural Finance Working Group, School of Business and Management, Queen Mary University of London
Prof. Karol Sikora MA, PhD, MBBChir, FRCP, FRCR, FFPM, Medical Director of Rutherford Health, Oncologist, & Dean of Medicine
Ask yourself WHY this isn't flooding every news station and WHY they're still pushing fear and death?!
What’s it going to take to get your name on this list @Michael Scally MD?
[OA] The Worldwide Clinical Trial Research Response to The COVID-19 Pandemic - The First 100 Days.
Background: Never before have clinical trials drawn as much public attention as those testing interventions for COVID-19. We aimed to describe the worldwide COVID-19 clinical research response and its evolution over the first 100 days of the pandemic.
Methods: Descriptive analysis of planned, ongoing or completed trials by April 9, 2020 testing any intervention to treat or prevent COVID-19, systematically identified in trial registries, preprint servers, and literature databases. A survey was conducted of all trials to assess their recruitment status up to July 6, 2020.
Results: Most of the 689 trials (overall target sample size 396,366) were small (median sample size 120; interquartile range [IQR] 60-300) but randomized (75.8%; n=522) and were often conducted in China (51.1%; n=352) or the USA (11%; n=76).
525 trials (76.2%) planned to include 155,571 hospitalized patients, and 25 (3.6%) planned to include 96,821 health-care workers. Treatments were evaluated in 607 trials (88.1%), frequently antivirals (n=144) or antimalarials (n=112); 78 trials (11.3%) focused on prevention, including 14 vaccine trials.
No trial investigated social distancing. Interventions tested in 11 trials with >5,000 participants were also tested in 169 smaller trials (median sample size 273; IQR 90-700). Hydroxychloroquine alone was investigated in 110 trials. While 414 trials (60.0%) expected completion in 2020, only 35 trials (4.1%; 3,071 participants) were completed by July 6.
Of 112 trials with detailed recruitment information, 55 had recruited <20% of the targeted sample; 27 between 20-50%; and 30 over 50% (median 14.8% [IQR 2.0-62.0%]).
Conclusions: The size and speed of the COVID-19 clinical trials agenda is unprecedented. However, most trials were small investigating a small fraction of treatment options. The feasibility of this research agenda is questionable, and many trials may end in futility, wasting research resources. Much better coordination is needed to respond to global health threats.
Janiaud P, Axfors C, Van't Hooft J, et al. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Res. 2020 Oct 2;9:1193. doi: 10.12688/f1000research.26707.1. PMID: 33082937; PMCID: PMC7539080. The worldwide clinical trial research response to... | F1000Research
Background: Never before have clinical trials drawn as much public attention as those testing interventions for COVID-19. We aimed to describe the worldwide COVID-19 clinical research response and its evolution over the first 100 days of the pandemic.
Methods: Descriptive analysis of planned, ongoing or completed trials by April 9, 2020 testing any intervention to treat or prevent COVID-19, systematically identified in trial registries, preprint servers, and literature databases. A survey was conducted of all trials to assess their recruitment status up to July 6, 2020.
Results: Most of the 689 trials (overall target sample size 396,366) were small (median sample size 120; interquartile range [IQR] 60-300) but randomized (75.8%; n=522) and were often conducted in China (51.1%; n=352) or the USA (11%; n=76).
525 trials (76.2%) planned to include 155,571 hospitalized patients, and 25 (3.6%) planned to include 96,821 health-care workers. Treatments were evaluated in 607 trials (88.1%), frequently antivirals (n=144) or antimalarials (n=112); 78 trials (11.3%) focused on prevention, including 14 vaccine trials.
No trial investigated social distancing. Interventions tested in 11 trials with >5,000 participants were also tested in 169 smaller trials (median sample size 273; IQR 90-700). Hydroxychloroquine alone was investigated in 110 trials. While 414 trials (60.0%) expected completion in 2020, only 35 trials (4.1%; 3,071 participants) were completed by July 6.
Of 112 trials with detailed recruitment information, 55 had recruited <20% of the targeted sample; 27 between 20-50%; and 30 over 50% (median 14.8% [IQR 2.0-62.0%]).
Conclusions: The size and speed of the COVID-19 clinical trials agenda is unprecedented. However, most trials were small investigating a small fraction of treatment options. The feasibility of this research agenda is questionable, and many trials may end in futility, wasting research resources. Much better coordination is needed to respond to global health threats.
Janiaud P, Axfors C, Van't Hooft J, et al. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Res. 2020 Oct 2;9:1193. doi: 10.12688/f1000research.26707.1. PMID: 33082937; PMCID: PMC7539080. The worldwide clinical trial research response to... | F1000Research
I've become a big James Corbett fan in last few months. Starting with his videos on Bill Gates.
I have not read any books by Klaus Schwab but something tells me to put them on my list of things to read. Will definitely look into it.
Between 130,000 and 210,000 COVID-19 deaths in the United States could have been avoided if the Trump administration had quickly and effectively implemented a cohesive public health response to the novel coronavirus, according to a new report. The report by Columbia University Earth Institute’s National Center for Disaster Preparedness, entitled “130,000 – 210,000 Avoidable COVID-19 Deaths — and Counting — in the U.S.,” compares the U.S. death toll and policy response to six similarly high-income countries: South Korea, Japan, Germany, Australia, France, and Canada. https://ncdp.columbia.edu/custom-content/uploads/2020/10/Avoidable-COVID-19-Deaths-US-NCDP.pdf
The new report suggests that if the U.S. followed similar policies and protocols as the six nations, such as building sufficient testing capabilities, enacting earlier lockdowns, issuing a national mask-wearing mandate, and providing federal guidance on social distancing, it could have avoided at least 130,000 and potentially as many as 210,000 COVID-19 deaths.
The report concludes there is a disproportionately high COVID-19 death rate in the U.S. compared to the other nations, even when examining median population age and obesity — two well-documented factors that affect COVID-19 mortality rates. ...
Jesus, stop with the Trump shit...
NO ONE CARES!
I looked up few sites to get the best average of total deaths in the US.
2017 Total Deaths: 2,813,503 (234,000/month)
2018 Total Deaths: 2,839,205 (237,000/month)
2019 Total Deaths: 2,855,000 (238,000/month)
2020 Total Deaths: (Jan thru 9/26): 2,130,000 (236,000/month) looks like 2020 is normal year, death wise.
Math over Media!
AKA: Logic and Reason
NO ONE CARES!
I looked up few sites to get the best average of total deaths in the US.
2017 Total Deaths: 2,813,503 (234,000/month)
2018 Total Deaths: 2,839,205 (237,000/month)
2019 Total Deaths: 2,855,000 (238,000/month)
2020 Total Deaths: (Jan thru 9/26): 2,130,000 (236,000/month) looks like 2020 is normal year, death wise.
Math over Media!
AKA: Logic and Reason
Wow. That's scary. But that's the point.
A Woman Died Of COVID-19 On A Commercial Flight
Some interesting things from the Buzzfeed article..
"It is unclear if the woman was aware that she had COVID-19 at the time of her death."
"Before the woman died, she had trouble breathing and was given oxygen, Jenkins told NBC 5 Dallas–Fort Worth. She also had underlying high-risk health conditions, officials said in a https://www.dallascounty.org/Assets/uploads/docs/covid-19/press-releases/october/101820-PressRelease-DallasCountyReports592AdditionalPositiveCOVID-19Cases.pdf Sunday."
And also..
"Trimble told BuzzFeed News that the woman’s case was a confirmed COVID-19 death, per the https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/"
I don't think I've seen it worded that way before. But here's the criteria for confirmed and probable, or..
https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/
Confirmed
- Meets confirmatory laboratory evidence.
I guess we have to assume she was tested, and that's why she died, back in July.
Last edited:
Similar threads
Sponsors
Latest posts
-
-
Sigma Audley Inc. - Your source for peptides, ancillaries, AAS, and more!- Latest: SigmaAudley China Peptide
-
Compounded Tirz has been vanquished. UGL likely next. Stock up.- Latest: AlexDavis43
-
